Login to Your Account

Northfield's PolyHeme Passes Third Phase III Interim Analysis

By Karen Pihl-Carey

Tuesday, April 12, 2005
Northfield Laboratories Inc.'s stock jumped 31.6 percent Monday after an independent data monitoring committee gave the go-ahead for the ongoing Phase III trial of PolyHeme. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription